Seelos Forges Ahead With SLS-002, Says Primary Endpoint Miss Due To Underpowered Trial

The company blamed lack of funding for incomplete enrollment of the Phase II study in acute suicidal ideation and behavior in major depressive disorder, saying it would have reached statistical significance had it fully enrolled.

Seelos plans to move ahead with SLS-002's development despite a primary endpoint miss in a Phase II study • Source: Shutterstock

More from Clinical Trials

More from R&D